{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:30:43Z","timestamp":1793021443135,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jacc.2019.01.056","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T15:47:53Z","timestamp":1555343273000},"page":"1931-1944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":600,"title":["Empagliflozin Ameliorates Adverse Left\u00a0Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics"],"prefix":"10.1016","volume":"73","author":[{"given":"Carlos G.","family":"Santos-Gallego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Requena-Ibanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"San Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotake","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Picatoste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Garcia-Ropero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.01.056_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.01.056_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.01.056_bib3","first-page":"297","article-title":"Metabolic origins of heart failure","volume":"2","author":"Wende","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Basic Transl Sci"},{"key":"10.1016\/j.jacc.2019.01.056_bib4","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.01.056_bib5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2019.01.056_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2019.01.056_bib7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2019.01.056_bib8","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.115.012427","article-title":"Sphingosine-1-phosphate receptor agonist\u00a0fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia\/reperfusion","volume":"133","author":"Santos-Gallego","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib9","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.115.020226","article-title":"Catabolic defect of branched-chain amino acids promotes heart failure","volume":"133","author":"Sun","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","article-title":"Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure","volume":"133","author":"Bedi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10557-018-6786-x","article-title":"Do the SGLT-2 inhibitors offer more than hypoglycemic activity?","volume":"32","author":"Flores","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2019.01.056_bib12","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","article-title":"Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus","volume":"37","author":"Marx","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.01.056_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2019.01.056_bib14","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1161\/01.CIR.102.25.3032","article-title":"Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial","volume":"102","author":"Theroux","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment","volume":"4","author":"Konstam","year":"2011","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2019.01.056_bib16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"on behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling\u2014concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.01.056_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.76.1.44","article-title":"Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction","volume":"76","author":"White","year":"1987","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/01.CIR.96.1.116","article-title":"End-systolic volume index is a strong predictor of early and late mortality","volume":"96","author":"Migrino","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jcmg.2008.05.012","article-title":"Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study","volume":"1","author":"Verma","year":"2008","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jacc.2019.01.056_bib20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ehj.2004.02.030","article-title":"Early identification of left ventricular remodelling after myocardial infarction, assessed by transthoracic 3D echocardiography","volume":"25","author":"Mannaerts","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.01.056_bib21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/01.CIR.94.4.690","article-title":"Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction","volume":"94","author":"Benedict","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa042330","article-title":"N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease","volume":"352","author":"Kragelund","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.01.056_bib23","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1073\/pnas.1016088108","article-title":"Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41)","volume":"108","author":"Kimura","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2019.01.056_bib24","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.jacc.2009.07.027","article-title":"Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging","volume":"54","author":"Kelle","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.01.056_bib25","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.jacc.2010.06.044","article-title":"Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction","volume":"56","author":"Hung","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.01.056_bib26","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.jacc.2018.02.064","article-title":"Global longitudinal strain to predict mortality in patients with acute heart failure","volume":"71","author":"Park","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.01.056_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/CIRCHEARTFAILURE.112.000228","article-title":"Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy","volume":"6","author":"Zhang","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.01.056_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1096\/fasebj.9.8.7768357","article-title":"Insulin, ketone bodies, and mitochondrial energy transduction","volume":"9","author":"Sato","year":"1995","journal-title":"FASEB J"},{"key":"10.1016\/j.jacc.2019.01.056_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.nutr.26.061505.111258","article-title":"Fuel metabolism in starvation","volume":"26","author":"Cahill","year":"2006","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.jacc.2019.01.056_bib30","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/dom.13297","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population-based cohort study","volume":"20","author":"Kim","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2019.01.056_bib31","doi-asserted-by":"crossref","first-page":"H1060","DOI":"10.1152\/ajpheart.00646.2012","article-title":"Ketone body metabolism and cardiovascular disease","volume":"304","author":"Cotter","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2019.01.056_bib32","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib33","first-page":"533","article-title":"Altered systemic ketone body metabolism in advanced heart failure","volume":"38","author":"Janardhan","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.jacc.2019.01.056_bib34","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.metabol.2017.08.005","article-title":"The diabetic heart utilizes ketone bodies as an energy source","volume":"77","author":"Mizuno","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2019.01.056_bib35","doi-asserted-by":"crossref","first-page":"e004417","DOI":"10.1161\/CIRCHEARTFAILURE.117.004417","article-title":"Cardiac-specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload-induced heart failure","volume":"10","author":"Uchihashi","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.01.056_bib36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.molmet.2014.07.010","article-title":"Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling","volume":"3","author":"Schugar","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacc.2019.01.056_bib37","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1161\/CIRCULATIONAHA.117.029733","article-title":"Inhibition of endothelial notch signaling impairs fatty acid transport and leads to metabolic and vascular remodeling of the adult heart","volume":"137","author":"Jabs","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib38","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.117.029166","article-title":"Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease","volume":"136","author":"Kappel","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.01.056_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-018-06850-0","article-title":"Rationale and design of the EMPA-TROPISM Trial (ATRU-4): Are the \u201ccardiac benefits\u201d of Empagliflozin independent of its hypoglycemic activity?","volume":"33","author":"Santos-Gallego","year":"2019","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719336897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719336897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:21:05Z","timestamp":1760016065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719336897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":39,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0735109719336897"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin Ameliorates Adverse Left\u00a0Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.01.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}